AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18577886
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg mosapride citrate
Trial: 18577886
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg itopride hydrochloride
Trial: 18577886
Drug: Vehicle (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (100 ml water) alone
Trial: 12492904
Drug: Control dentifrice
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control dentifrice (without anti‐plaque agents)
Trial: 10048684
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplements (400,000 IU); given at baseline, 4 months, and 8 months after discharge.
Trial: 8579884
Drug: Webril patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Webril patch
Trial: 8579884
Drug: Hill Top
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hill Top patch
Trial: 2405789
Drug: Dipyridamole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (5 mg/kg/day) for 12 months
Trial: 6767959
Drug: Gentamicin once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin once daily (120 mg)
Trial: 6767959
Drug: Gentamicin twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin twice daily (40/80 mg)
Trial: 6767959
Drug: Gentamicin three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin three times daily (40 mg)
Trial: 26831124
Drug: enalapril-lercanidipine (EL)
RxNorm normalized name: enalapril and lercanidipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril-lercanidipine (EL) uptitrated to 20 mg/d
Trial: 26831124
Drug: enalapril-felodipine (EF)
RxNorm normalized name: enalapril / felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril-felodipine (EF) uptitrated to 10 mg/d
Trial: 24559212
Drug: Complex small
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex small group educational seminar on antibiotic prescribing
Trial: 22251408
Drug: Paricalcitol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (mean initiation dose: 23 ± 7 μg/week)
Trial: 21570554
Drug: Oral Contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Contraceptives (OC)
Trial: 17236845
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) mechanical bowel preparation
Trial: 17236845
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium phosphate (SP) mechanical bowel preparation
Trial: 17236845
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium phosphate (SP) with ertapenem antibiotic prophylaxis
Trial: 17236845
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) with cefotetan antibiotic prophylaxis
Trial: 15059701
Drug: Valganciclovir therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir therapy (900 mg daily)
Trial: 15059701
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of valganciclovir therapy
Trial: 15059701
Drug: Valganciclovir therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir therapy
Trial: 10689236
Drug: Oral ETEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ETEC B-subunit-inactivated whole cell vaccine
Trial: 9342768
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg hypericum extract (LI 160)
Trial: 9342768
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg hypericum extract (LI 160)
Trial: 9342768
Drug: 3600 mg
RxNorm normalized name: Ascorbic Acid/Calcium 3600 MG-400 MG Oral Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3600 mg hypericum extract (LI 160)
Trial: 9342768
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg hypericum extract t.i.d. (5.6 mg total hypericin daily)
Trial: 28230596
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement with lyophilized bovine bone granules and pericardium membrane covering
Trial: 28230596
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (immediate implants)
Trial: 21845472
Drug: Naftopidil 10
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 10 mg once daily
Trial: 18482350
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltaren 3 x 50 mg)
Trial: 18482350
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Diclofenac and Occlusal splint therapy)
Trial: 10834776
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of isobaric bupivacaine with 25 microg fentanyl
Trial: 10834776
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of isobaric (plain) bupivacaine 0.5%
Trial: 9489085
Drug: Doxazosin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (0.5 or 1 mg once daily, up to 12 mg once daily)
Trial: 8161441
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment (exact dosage and duration not specified)
Trial: 3526984
Drug: Esmolol (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (infusion rates between 100 and 300 micrograms X kg‐1 X min‐1)
Trial: 30070386
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (average duration: 9 weeks)
Trial: 24121610
Drug: Subgluteal space
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subgluteal space technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Trial: 24121610
Drug: Infragluteal technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infragluteal technique (30 mL admixture of 1:2 lidocaine 2% and bupivacaine 0.5% with 1:200,000 epinephrine)
Trial: 17951021
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment (SC) as an adjunct to substance abuse treatment-as-usual (TAU)
Trial: 17951021
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment (SC)
Trial: 17951021
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment-as-usual (TAU)
Trial: 14983955
Drug: Serum prostate-specific
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum prostate-specific antigen (PSA) determination, digital rectal examination (DRE), transrectal ultrasonography (TRUS) as screening tests
Trial: 14983955
Drug: Serum PSA
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PSA level > or = 3.0 ng/mL as an indication for sextant biopsy
Trial: 7986334
Drug: Live VZV
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live VZV vaccine (4,000 PFU of Oka strain)
Trial: 7986334
Drug: Inactivated VZV
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated VZV vaccine (similar amount to live vaccine)
Trial: 7986334
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid (TT) immunization (3 months before VZV vaccine)
Trial: 3151688
Drug: Clindamycin 3x80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 3x80 mg and Gentamycin 3x80 mg
Trial: 3151688
Drug: Metronidazol 3x500
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazol 3x500 mg and Gentamycin 3x80 mg
Trial: 25211695
Drug: Order of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Order of administration with memory descriptions before well-being scales
Trial: 25211695
Drug: Order of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Order of administration with well-being scales before memory descriptions
Trial: 23594227
Drug: MK-0916 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0916 (6 mg once daily for 14 days)
Trial: 23594227
Drug: MK-0916 (0.4-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0916 (0.4-100 mg single doses)
Trial: 23594227
Drug: MK-0916 (0.2-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0916 (0.2-225 mg followed by daily doses of 0.2-100 mg for 13 days)
Trial: 15131466
Drug: Licensed meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed meningococcal polysaccharide vaccine (A, C, Y, W-135) at 15 to 18 months
Trial: 11237270
Drug: Etidronate (2-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (2-week administration)
Trial: 2277738
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (0.5 mg b.i.d.)
Trial: 23432146
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 or 40 mg once daily for 4 weeks
Trial: 23432146
Drug: Current therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapy (control)
Trial: 21310833
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g Acetyl-L-carnitine (ALC) twice a day for 90 days
Trial: 21310833
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 90 days
Trial: 10471608
Drug: p55‐IgG, 0.083
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p55‐IgG, 0.083 mg/kg
Trial: 9153367
Drug: p55‐IgG, 0.042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p55‐IgG, 0.042 mg/kg
Trial: 9153367
Drug: p55‐IgG (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p55‐IgG (both doses)
Trial: 8162628
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg isosorbide dinitrate (ISDN) treatment for 4 weeks
Trial: 8162628
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of glyceryl trinitrate (GTN) before ISDN treatment
Trial: 8162628
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of glyceryl trinitrate (GTN) after ISDN treatment
Trial: 31853557
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg LSD
Trial: 31853557
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg LSD
Trial: 31853557
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg LSD
Trial: 28746179
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of NBP soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Trial: 28746179
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of placebo soft capsules orally, 15 minutes before each meal, 3 times daily for 21 days
Trial: 23039152
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual therapy)
Trial: 18090507
Drug: Escitalopram (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10‐20 mg/day)
Trial: 1597847
Drug: Nicardipine 30
RxNorm normalized name: niCARdipine 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 30 mg three times daily for four weeks
Trial: 30414369
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (calcium channel blockers plus oxygen‐ozone treatment)
Trial: 30414369
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (calcium channel blockers only)
Trial: 24556445
Drug: ECV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECV with antiarrhythmic drugs (mostly amiodarone)
Trial: 24556445
Drug: PCV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV with class Ic antiarrhythmic drugs
Trial: 24556445
Drug: Chronic antiarrhythmic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic antiarrhythmic drugs, beta-blockers, or inhibitors of the renin-angiotensin system
Trial: 22098133
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus L. gasseri-containing yogurt (112 g, twice daily for 4 weeks)
Trial: 22098133
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Trial: 22098133
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus L. gasseri-containing yogurt
Trial: 1100308
Drug: Intravenous phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous phenytoin
Trial: 14985668
Drug: Intravenous fosphenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosphenytoin
Trial: 14985668
Drug: Oral phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral phenytoin vs Intravenous phenytoin
Trial: 14985668
Drug: Intravenous fosphenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosphenytoin vs Intravenous phenytoin
Trial: 8052154
Drug: D-fenfluramine 15
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-fenfluramine 15 mg twice daily
Trial: 26634956
Drug: Buprenorphine (BBUP)
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine (BBUP) 150-450 µg every 12 hours
Trial: 21931012
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser treatment (EVLT)
Trial: 20873270
Drug: Nutrition optimization
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition optimization as part of maintenance therapy
Trial: 9347122
Drug: d-amphetamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (0.25 mg/kg)
Trial: 16815467
Drug: levodopa/carbidopa (100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa/carbidopa (100/25 mg)
Trial: 1448534
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheets (Spenco) worn continuously for 12 hours for 12 weeks
Trial: 1448534
Drug: Kenalog injection
RxNorm normalized name: triamcinolone Injection [Kenalog]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kenalog injection (40 mg/ml x 1 cc mixed with 1 cc of 1% Xylocaine with epinephrine)
Trial: 2864962
Drug: Phosphatidylcholine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine (30 g/day)
Trial: 29056072
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (Intervention)
Trial: 27809796
Drug: 8-week web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week web-based stress management intervention (STREAM) with weekly written feedback by a psychologist
Trial: 20136803
Drug: Vacuum interferential
RxNorm normalized name: thymol
DrugBank: Thymol (DB02513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vacuum interferential current (IFC) therapy
Trial: 12826548
Drug: Postoperative local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative local anesthetics and supplemental analgesics
Trial: 9864004
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 100 microg once daily
Trial: 9864004
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 200 microg once daily
Trial: 9864004
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 100 microg twice daily
Trial: 1442757
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 to 40 mg/d)
Trial: 3910296
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 280 mg mefloquine, 800 mg sulfadoxine and 40 mg pyrimethamine
Trial: 3910296
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 420 mg mefloquine, 1200 mg sulfadoxine and 60 mg pyrimethamine
Trial: 3910296
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1500 mg sulfadoxine and 75 mg pyrimethamine
Trial: 18076041
Drug: Highest quintile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quintile of triglycerides (>/=160 mg/dl)
Trial: 18076041
Drug: Lowest quintile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest quintile of HDL (<30 mg/dl)
Trial: 15309442
Drug: Rye bran
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rye bran breads (10.2 mg ferulic acid per day)
Trial: 9223886
Drug: Albumin and
RxNorm normalized name: Bovine serum albumin and glutaraldehyde only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin and lactated Ringer solution (Group III)
Trial: 8267190
Drug: Open-label continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label continuous epidural infusion of clonidine (10-50 micrograms/h)
Trial: 28951026
Drug: Coping partnership
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping partnership intervention (1 home visit, weekly telephone calls for month 1, biweekly calls for months 2 and 3)
Trial: 17074300
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy (CBT) in RCT (N=30)
Trial: 17074300
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy (CBT) in routine practice (N=384)
Trial: 12099542
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% three times daily for 12 weeks
Trial: 12099542
Drug: Acetazolamide 250-mg
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250-mg q.i.d. for 12 weeks
Trial: 10847958
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of gas flow through the perfusate before bypass, starting FIO2 of 0.80
Trial: 10847958
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of gas flowing through the perfusate, starting FIO2 of 0.21
Trial: 8678268
Drug: glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glucose solution + lipid emulsion
Trial: 8678268
Drug: fructose solution
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fructose solution + lipid emulsion
Trial: 1964153
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (1000 mg/m2 cyclophosphamide, 50 mg/m2 doxorubicin, 1.4 mg/m2 vincristine)